<DOC>
	<DOCNO>NCT00909961</DOCNO>
	<brief_summary>This study evaluate effect zoledronic acid 5 mg infusion BMD biochemical marker bone post-menopausal osteoporotic patient age 50-65 .</brief_summary>
	<brief_title>A Trial Evaluating Effects Zoledronic Acid 5 mg Infusion Bone Mineral Density ( BMD ) Postmenopausal Osteoporosis ( PMO ) Patients Between Ages 50 65 Years</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Postmenopausal osteoporosis Patients low bone mineral density hip vertebral Patients osteoporotic fracture hip vertebra Hypersensitivity either active substance excipients biphosphonates . Known metabolic bone disease exclude osteoporosis . Serious systemic disorder treat drug interfere bone metabolism . Significant liver renal failure Pathologic fracture examine body area elsewhere . Previous antiosteoporotic treatment within 12 month less prior recruitment . Patients hypocalcaemia Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Bone Mineral Density</keyword>
	<keyword>Biomarkers</keyword>
</DOC>